Decreased half life of cyclophosphamide in patients under continual treatment

Maurizio D'Incalci, Giorgio Bolis, Terenzio Facchinetti, Costantino Mangioni, Luciano Morasca, Paolo Morazzoni, Mario Salmona

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Plasma levels of cyclophosphamide (Cy) were measured in 16 cancer patients receiving 100 mg/day of Cy for over 1 yr. Oral and intravenous administrations gave similar AUC values, confirming that intestinal absorption is almost complete. When pharmacokinetics obtained at the first course of therapy were compared with pharmacokinetics measured after more than 6 months continual treatment, T 1 2 and Vd appeared significantly lower in the second population despite broad variability among patients.

Original languageEnglish
Pages (from-to)7-10
Number of pages4
JournalEuropean Journal of Cancer (1965)
Volume15
Issue number1
DOIs
Publication statusPublished - 1979

Fingerprint

Cyclophosphamide
Half-Life
Pharmacokinetics
Intestinal Absorption
Intravenous Administration
Area Under Curve
Oral Administration
Therapeutics
Population
Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

Decreased half life of cyclophosphamide in patients under continual treatment. / D'Incalci, Maurizio; Bolis, Giorgio; Facchinetti, Terenzio; Mangioni, Costantino; Morasca, Luciano; Morazzoni, Paolo; Salmona, Mario.

In: European Journal of Cancer (1965), Vol. 15, No. 1, 1979, p. 7-10.

Research output: Contribution to journalArticle

D'Incalci, Maurizio ; Bolis, Giorgio ; Facchinetti, Terenzio ; Mangioni, Costantino ; Morasca, Luciano ; Morazzoni, Paolo ; Salmona, Mario. / Decreased half life of cyclophosphamide in patients under continual treatment. In: European Journal of Cancer (1965). 1979 ; Vol. 15, No. 1. pp. 7-10.
@article{b38518acc3db46d397177e5f058ab274,
title = "Decreased half life of cyclophosphamide in patients under continual treatment",
abstract = "Plasma levels of cyclophosphamide (Cy) were measured in 16 cancer patients receiving 100 mg/day of Cy for over 1 yr. Oral and intravenous administrations gave similar AUC values, confirming that intestinal absorption is almost complete. When pharmacokinetics obtained at the first course of therapy were compared with pharmacokinetics measured after more than 6 months continual treatment, T 1 2 and Vd appeared significantly lower in the second population despite broad variability among patients.",
author = "Maurizio D'Incalci and Giorgio Bolis and Terenzio Facchinetti and Costantino Mangioni and Luciano Morasca and Paolo Morazzoni and Mario Salmona",
year = "1979",
doi = "10.1016/0014-2964(79)90198-1",
language = "English",
volume = "15",
pages = "7--10",
journal = "European Journal of Cancer",
issn = "0014-2964",
publisher = "Elsevier Ltd",
number = "1",

}

TY - JOUR

T1 - Decreased half life of cyclophosphamide in patients under continual treatment

AU - D'Incalci, Maurizio

AU - Bolis, Giorgio

AU - Facchinetti, Terenzio

AU - Mangioni, Costantino

AU - Morasca, Luciano

AU - Morazzoni, Paolo

AU - Salmona, Mario

PY - 1979

Y1 - 1979

N2 - Plasma levels of cyclophosphamide (Cy) were measured in 16 cancer patients receiving 100 mg/day of Cy for over 1 yr. Oral and intravenous administrations gave similar AUC values, confirming that intestinal absorption is almost complete. When pharmacokinetics obtained at the first course of therapy were compared with pharmacokinetics measured after more than 6 months continual treatment, T 1 2 and Vd appeared significantly lower in the second population despite broad variability among patients.

AB - Plasma levels of cyclophosphamide (Cy) were measured in 16 cancer patients receiving 100 mg/day of Cy for over 1 yr. Oral and intravenous administrations gave similar AUC values, confirming that intestinal absorption is almost complete. When pharmacokinetics obtained at the first course of therapy were compared with pharmacokinetics measured after more than 6 months continual treatment, T 1 2 and Vd appeared significantly lower in the second population despite broad variability among patients.

UR - http://www.scopus.com/inward/record.url?scp=0018772548&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018772548&partnerID=8YFLogxK

U2 - 10.1016/0014-2964(79)90198-1

DO - 10.1016/0014-2964(79)90198-1

M3 - Article

VL - 15

SP - 7

EP - 10

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0014-2964

IS - 1

ER -